Literature DB >> 3791601

Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with acute myocardial infarction.

K A Johannessen, J E Nordrehaug, G von der Lippe.   

Abstract

To examine whether early intervention with timolol influences the occurrence of left ventricular thrombi in acute anterior myocardial infarction, 40 patients with acute anterior myocardial infarction admitted to hospital within 6 hr of onset of symptoms were randomly assigned to receive intravenous followed by oral timolol maleate or placebo. Five (25%) of 20 patients in the placebo group and 14 (73.7%) of 19 patients with confirmed infarction in the timolol group developed a left ventricular apical thrombus as detected by two-dimensional echocardiography from 2 to 10 days after inclusion (p less than .005). Patients received anticoagulants only after a left ventricular thrombus had been diagnosed. Only one patient with thrombus suffered peripheral embolization (timolol group). The treatment groups were comparable with respect to location of regional left ventricular dysfunction, electrocardiographic changes, and infarct size estimated by creatine kinase release. However, computer-assisted regional wall motion analysis demonstrated significantly reduced apical wall motion in the timolol group compared with the placebo group (p less than .01). Also, the mean heart rate during the first 10 days after the acute infarction was reduced by 13% in the timolol group (p less than .001). The reduction in heart rate and left ventricular apical wall motion caused by timolol in patients with acute anterior myocardial infarction may increase the occurrence of left ventricular thrombi.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3791601     DOI: 10.1161/01.cir.75.1.151

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors:  J H Jansson; B Johansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  According to MIAMI and ISIS-I trials, can a general recommendation be given for beta blockers in acute myocardial infarction?

Authors:  J K Kjekshus
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

3.  Effects of three beta-blockers with different pharmacodynamic properties on platelet aggregation and platelet and plasma cyclic AMP.

Authors:  K Winther; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy.

Authors:  G Y Lip
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 5.  Common causes of cardiac emboli--left ventricular thrombi and atrial fibrillation.

Authors:  J R Stratton
Journal:  West J Med       Date:  1989-08

6.  Effect of felodipine, a new calcium channel antagonist, on platelet function and fibrinolytic activity at rest and after exercise.

Authors:  H Sengeløv; K Winther
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Risk factors for embolisation in patients with left ventricular thrombi and acute myocardial infarction.

Authors:  K A Johannessen; J E Nordrehaug; G von der Lippe; S E Vollset
Journal:  Br Heart J       Date:  1988-08

8.  Differential effects of timolol and metoprolol on platelet function at rest and during exercise.

Authors:  K Winther; J B Knudsen; E O Jørgensen; E Eldrup
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Neutrophil Lymphocyte Ratio as a Predictor of Left Ventricular Apical Thrombus in Patients with Myocardial Infarction.

Authors:  Ahmet Goktug Ertem; Filiz Ozcelik; Haci Ahmet Kasapkara; Cemal Koseoglu; Serdal Bastug; Huseyin Ayhan; Cenk Sari; Nihal Akar Bayram; Emine Bilen; Tahir Durmaz; Telat Keles; Engin Bozkurt
Journal:  Korean Circ J       Date:  2016-11-01       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.